Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- T cells and oncology
- Therapeutic use T cells
- Therapeutic use of gene engeneered T cells (1)
- Chimeric Antigen Receptors (CAR)
- Anti-CD19 CAR T cells: clinical responses (1)
- Anti-CD19 CAR T cells: clinical responses (2)
- Anti-CD19 CAR T cells: clinical responses in diffuse large B cell lymphoma
- Successful treatment with CAR T cells
- F.D.A. approved treatment
- Toxicities associated with CAR T cell therapy: Cytokine Release Syndrom (CRS)
- Therapeutic use of gene engeneered T cells (2)
- Therapeutic use of T cells: TCR vs. CAR (1)
- Therapeutic use of T cells: TCR vs. CAR (2)
- TCR vs. CAR: advantages and disadvantages
- TCR vs. CAR: mode of action
- Common effector molecules for CAR and TCR T cells
- Issues associated with anti-CD19-CAR T cell therapies
- Limited applicability of CAR T cells outside of hematological malignancies so far
- The bottlenecks to CAR T cell therapy efficacy in solid tumors
- Potential solutions - by means of engineering
- Acknowledgements
- Disclosures
Topics Covered
- Introduction to therapeutic use of T cells
- Clinical use of CAR T cell therapy
- CAR T cell therapy mode of action of
- Differences to TCR T cell therapy
- Resistance mechanisms to CAR T cell therapy
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Kobold, S. (2020, November 30). Mode of action of T cells engineered with CAR or TCR for cancer treatment [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 25, 2021, from https://hstalks.com/bs/4459/.Publication History
Financial Disclosures
- Sebastian Kobold (S.K.) has licensed IP to TCR2 Inc, Boston. S.K. has received research support from TCR2 Inc and Arcus Biosciences. S.K. serves on the scientific advisory board of TCR2 Inc and on various scientific advisory boards of Novartis.
Mode of action of T cells engineered with CAR or TCR for cancer treatment
Published on November 30, 2020
36 min
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Hide